Precision Psychiatric Sexual Wellness

Sexual function is often a reflection of mood, hormones, medication burden, and nervous system state

Desire loss, erectile dysfunction, impaired arousal, orgasmic dysfunction, and intimacy-related distress are rarely isolated symptoms. They often emerge at the intersection of depression, anxiety, trauma, hormonal dysregulation, autonomic overactivation, and psychotropic side effects. At Welmivia, sexual wellness is approached as a clinical problem requiring evaluation, targeted laboratory review when indicated, and precision treatment selection — not a transactional prescription model.

Schedule a Fit Call
  • Category 1 — Desire & Libido Dysregulation
  • Category 2 — Erectile Function & Performance Anxiety
  • Category 3 — Female Sexual Dysfunction
  • Category 4 — Medication-Induced Sexual Dysfunction
  • Category 5 — Hormonal & Relational Drivers

Eval First

Initial psychiatric assessment required

Labs When Indicated

Hormonal and metabolic review

Rx Separate

Medications billed outside Welmivia

Monitored Care

Ongoing therapy within established follow-up

Clinical Scope What this page includes

Sexual symptoms are often a diagnostic clue, not a side concern

Sexual dysfunction is commonly dismissed as secondary when it is often one of the clearest markers that a psychiatric treatment plan, hormonal substrate, or medication regimen is not yet optimized. At Welmivia, sexual symptoms are evaluated through a psychiatric lens: what is suppressing desire, blunting reward, impairing arousal, reducing erectile reliability, or disrupting orgasmic function?

This includes antidepressant-related sexual dysfunction, performance anxiety, trauma-linked shutdown, perimenopausal decline, low testosterone, autonomic dysregulation, and broader cases where sexual symptoms track with mood, cognition, energy, stress physiology, or relational strain.

Important: Sexual wellness treatment at Welmivia is not initiated on medication request alone. Every intervention requires documented clinical rationale, psychiatric relevance, and when appropriate, targeted laboratory or medication-history support linking the symptom pattern to a treatable mechanism.

Treatment Domains What Welmivia evaluates

A structured framework for sexual wellness evaluation

Libido / Desire Loss

Domain 1
Depression · Hormonal insufficiency · Stress-mediated suppression

Low desire may reflect depressive physiology, serotonergic burden, testosterone or estradiol deficiency, chronic stress, trauma-linked shutdown, or a psychiatric regimen that reduces symptoms without restoring reward and motivation.

  • Loss of sexual interest despite emotional attachment
  • Anhedonia and flattened reward response
  • Perimenopausal or androgen-related decline
  • Medication-induced desire suppression

Arousal / Erectile Function

Domain 2
Performance anxiety · Autonomic overactivation · Vascular/hormonal contribution

Erectile dysfunction is not always purely vascular. In many patients it is reinforced by anticipatory anxiety, psychotropic side effects, sympathetic overactivation, hormonal decline, or repeated failure cycles that convert a transient issue into a persistent one.

  • Inconsistent or situational erectile reliability
  • Performance anxiety and cognitive interference
  • Medication-related erectile dysfunction
  • Psychiatric and hormonal contribution to arousal failure

Sildenafil / Tadalafil

PDE-5
Erectile response · Confidence restoration · Psychophysiologic support

PDE-5 inhibitors may improve erectile response, but at Welmivia they are not prescribed as convenience medications. Their use is considered in the context of psychiatric symptoms, medication burden, cardiometabolic status, hormonal contribution, and the degree to which anxiety has become part of the dysfunction itself.

  • Selected erectile dysfunction cases
  • Medication-induced erectile impairment
  • Performance anxiety with physiologic reinforcement
  • May be combined with broader psychiatric optimization

Vyleesi / Oxytocin / Trimix

Adjunctive
Desire · Relational salience · Escalation pathways

Selected adjunctive agents may be appropriate in carefully screened cases. Vyleesi may be considered in selected women with hypoactive desire. Oxytocin may be considered in highly specific relational or psychophysiologic presentations. Trimix is an escalation pathway, not first-line care, and requires clear documentation, education, and screening.

  • Case selection over protocolized prescribing
  • Never a substitute for diagnostic clarity
  • Used only within an established treatment relationship
  • Clinical rationale must be documented

How Welmivia approaches sexual wellness

Framework

The goal is not simply to improve sexual performance. The goal is to restore sexual function as part of a broader improvement in mood, energy, confidence, relational capacity, embodiment, and overall psychiatric outcome. In many patients, the most effective intervention is not adding another medication — it is correcting the regimen, hormonal substrate, or psychiatric formulation causing the dysfunction.

Medication Review

Evaluate antidepressants, mood stabilizers, antipsychotics, or other agents that may be suppressing libido, impairing orgasm, or blunting reward circuitry.

Hormonal Logic

Assess testosterone, estradiol, progesterone, thyroid, DHEA, and metabolic factors when the presentation suggests endocrine contribution.

Psychiatric Relevance

Determine whether sexual symptoms are linked to depression, anxiety, trauma, stress physiology, or relational dysregulation rather than treating them as isolated complaints.

Takeover Cases Accepted

Case-by-case
Independent review · Baseline reassessment · Framework alignment

If a patient is already receiving sexual wellness or hormone-adjacent treatment elsewhere, transfer of care may be possible. Prior prescribing patterns, goals, or formulations may not align with Welmivia’s precision psychiatric model, so takeover requires independent reassessment.

  • Full prior treatment history required
  • Response, side effects, and dose history reviewed
  • Continuation is not automatic
  • Treatment targets must fit Welmivia scope

What Reassessment Includes

Required
Psychiatric diagnosis · Labs when indicated · Medication burden

Takeover evaluation focuses on whether the current sexual wellness treatment still makes clinical sense once mood disorder, anxiety, trauma, hormone status, and medication burden are reviewed within a psychiatric framework.

  • Updated psychiatric formulation
  • Independent baseline labs when indicated
  • Review of medication burden and interaction risks
  • Decision on whether continuation is appropriate

Qualifying Patterns Where this fits clinically

Where sexual symptoms meet psychiatric diagnosis

Sexual wellness treatment at Welmivia is intended for symptom patterns with clear psychiatric, medication-mediated, hormonal, or stress-physiology relevance. Common examples include antidepressant-related sexual dysfunction, performance anxiety, trauma-related inhibition, low desire in depressive states, perimenopausal sexual decline, and hormonally mediated loss of libido or arousal.

Patients seeking purely transactional erectile dysfunction treatment, fertility care, STI management, pelvic pain treatment, or procedural urologic/gynecologic care are outside Welmivia scope.

Included / Excluded Scope boundaries

Included: libido loss, erectile dysfunction, orgasmic dysfunction, antidepressant sexual side effects, female sexual dysfunction, hormonal contribution, performance anxiety, takeover cases, relational/psychiatric contributors.

Excluded: STI care, fertility treatment, pelvic pain disorders, procedural urology, procedural gynecology, and purely cosmetic or non-clinically indicated “enhancement” requests.

Care Pathway How treatment starts

Sexual wellness at Welmivia begins with evaluation, not medication request

1. Initial Evaluation

$450 entry point

Every patient begins with a full psychiatric evaluation and Welmivia Blueprint. This includes review of sexual symptoms, medication history, hormonal logic, mood and anxiety relevance, and whether sexual wellness treatment fits within scope. Ongoing care is not initiated through a fit call alone.

2. Labs & Monitoring

Direct-pay labs · medications separate

Targeted laboratory review may include testosterone, estradiol, progesterone, thyroid markers, CBC, CMP, lipids, and other clinically relevant studies when indicated. Labs are ordered by the physician and paid directly by the patient through LabCorp or Quest. Medications are billed separately from Welmivia.

3. Ongoing Treatment

Established follow-up care

Treatment adjustments, side-effect monitoring, erectile function support, desire-focused treatment, hormonal review, and other adjunctive prescribing occur within established follow-up care and, when appropriate, the membership framework. This is monitored care — not open-ended prescription access.

4. Membership Context

For ongoing monitored adjunctive therapy

Welmivia’s operating model is built around structured follow-up and monitored adjunctive therapy access for established patients. Sexual wellness treatments requiring ongoing titration, review, or coordinated optimization are managed within that broader framework rather than as one-off transactional prescriptions.

FAQ Common questions

Questions patients commonly ask about sexual wellness treatment

Does Welmivia prescribe sildenafil or tadalafil on request alone?
No. These medications are considered only after clinical review of psychiatric, hormonal, medical, and medication-related drivers contributing to the symptom pattern.
Is this only for men?
No. Welmivia evaluates sexual dysfunction in both men and women, including low desire, arousal dysfunction, antidepressant-related sexual side effects, perimenopausal decline, and hormonally mediated changes in sexual function.
What if my symptoms started after an antidepressant?
That is one of the most common reasons patients seek evaluation. Welmivia reviews whether the current psychiatric regimen is suppressing libido, impairing orgasm, reducing arousal, or blunting reward and then determines whether the best intervention is adjustment, augmentation, hormonal support, or a more targeted sexual wellness strategy.
Are hormones always part of the workup?
Not always — but they are considered whenever the presentation suggests testosterone deficiency, estradiol decline, progesterone loss, thyroid dysfunction, neurosteroid depletion, or broader endocrine contribution to psychiatric and sexual symptoms.
Can I transfer care if I’m already on treatment elsewhere?
Possibly. Takeover is case-by-case and requires full evaluation, independent review, and alignment with Welmivia’s treatment framework.

Precision Psychiatric Sexual Wellness

Sexual symptoms deserve real clinical interpretation

When sexual function changes, the answer is not always “add another prescription.” Sometimes the problem is depression that never fully resolved, an antidepressant that flattened desire, a hormonal substrate that was never evaluated, or an anxiety pattern that turned physiology into avoidance. Welmivia approaches sexual wellness as part of precision psychiatric care.

Book a Fit Call

Welmivia is a direct-pay psychiatric practice. Fit calls are screening calls only and not clinical visits. All treatment requires clinical evaluation and appropriateness within scope. Medications are billed separately. Labs are ordered by the physician and paid directly by the patient.